Benzinga’s Top Ratings Upgrades, Downgrades For March 28, 2023
Upgrades For Coherus BioSciences Inc (NASDAQ:CHRS), UBS upgraded the previous rating of Neutral to Buy. Coherus BioSciences earned…
Wedbush Reiterates Outperform on Geron, Maintains $6 Price Target
Wedbush analyst Robert Driscoll reiterates Geron (NASDAQ:GERN) with a Outperform and maintains $6 price target.
Needham Maintains Buy on Geron, Raises Price Target to $4
Needham analyst Gil Blum maintains Geron (NASDAQ:GERN) with a Buy and raises the price target from $3 to $4.
Reported Late Thursday, Geron Corporation Announces Pricing Of $198M Upsized Public Offering Of 55,876,297 Shares Of Common Stock At A Price Of $2.45/Share
Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of an upsized underwritten public offering consisting of 55,876,297 shares of its common stock at a public offering price of $2.45 per share and pre-funded warrants to purchase 25,000,000 shares of its com
Exclusive: 5 Stocks To Watch From Benzinga Moneymaker Index, One Large Cap And 4 Small Cap Names
Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities.
Constellation Brands, Walgreens, RPM International And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Dow Jones dropping more than 300 points on Thursday. Here are some big stocks recording gains in today’s session.
Why Geron Stock Is Falling After Hours
Geron Corp (NASDAQ: GERN) shares are trading lower in Wednesday's after-hours session after the company announced a
Geron Corporation Announces $175M Proposed Public Offering Of Common Stock
Geron Corporation (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell $175 million of shares of its common stock in an underwritten public offering.
Dow Gains 150 Points After Fed Minutes
U.S. stocks traded higher toward the end of trading, following the release of minutes from the FOMC meeting.
Why Enovix Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Vivos Therapeutics, Inc. (NASDAQ: VVOS) shares surged 204% to $2.25 after the company announced it received FDA 510(k) clearance for its DNA oral appliance for the treatment of obstructive sleep apnea.